Recent advances in emerging technologies, including generative artificial intelligence, could fundamentally reshape the biotechnology industry.
“We live through the 'hinge moments.' We combine technology and biotechnology to revolutionize drug discovery, development, manufacturing and commercialization,” said David Reese, Amgen's Chief Technology Officer. “Amgen is focused on accelerating the delivery of new treatments, while also providing employees with access to industry-leading tools to enable their mission to serve patients.”
Sean Bruich, Amgen's SVP, Artificial Intelligence and Data, explains the potential impacts of Openai's GPT-5.
Amgen was an early adopter of Openai's ChatGpt Enterprise, and as capacity grew, Access was expanded internally. This gradual rollout enabled security-supported measurement testing that allows technology to be integrated into meaningful workflows across the enterprise.
As part of a strong collaboration with Amgen and Openai, Amgen scientists and engineers had the opportunity to evaluate Openai's latest frontier model, GPT-5, as a continuing commitment to leadership in advancing artificial intelligence applications in the field of biotechnology.
“Based on our internal assessment, GPT-5 shows significant improvements in objective measures such as accuracy and reliability, but equally important is qualitative feedback from our team, reporting improvements in production quality.” “These are important indicators for companies like Amgen, and it is essential to maintain high-quality standards for scientific accuracy and decision-making.”
Every breakthrough in new features related to Openai's model not only has the potential to improve the performance of existing workflows, but also opens the door to new use cases to support Amgen's mission to serve patients.
